Dorlands Medical Dictionary defines abulia as an "inability to perform acts voluntarily or to make decisions." The term derives from the Greek and literally means absence of will. Although widely used in late nineteenth century psychiatry the term fell out of use thereafter, but has been revived in the past decade to describe problems of drive and volition arising as a result of brain damage. Fisher' recommended the use of the term to describe "a specific neurological syndrome comprising slowness, decreased responsiveness, apathy . . . Akinetic mutism is its extreme form." Fisher' reviewed the literature on organic abulia/akinetic mutism and described 37 cases from his own clinical experience. The state arose from bilateral cingulate lesions in 11 cases, midbrain/medial diencephalic lesions in 18, hydrocephalus in nine, third ventricle cysts in three. Craniopharyngioma, encephalitis lethargica and trauma accounted for one each. Ross apathy associated with lack of in spontaneity. He was initially thou cognitively impaired but this proves the case on formal testing. He livei parents and required prompting to his personal hygiene and spent X watching TV, looking at magazine: nothing, and had little concern ove watched or read. He was, however, c
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Discussion
The cases we report justify the revival of interest in the syndrome of abulia, occurring following brain damage. The potential value of dopamine agonists in its treatment is also highlighted. This appears to apply not only when abulia is at the severity of akinetic mutism, as in previously reported cases, but also at lesser severities. Withdrawal or reduction of bromocriptine in three cases resulted in rapid deterioration, and the brief use of a dopamine antagonist (sulpiride) had a similar effect. The effectiveness ofsulpiride in counteracting the beneficial effects ofbromocriptine on abulia may give a clue as to the nature of the brain systems that are important in the generation ofabulia. Sulpiride is a selective antagonist of D2 receptors which act independently of adenylate cyclase.8 It appears therefore that these receptors are particularly important in the mediation of drive and motivation.
In case four bromocriptine was withdrawn, due to the development of a depressive disorder. Lisuride, a recently introduced dopamine agonist of greater potency than bromocriptine,9 was introduced with good effect, but there remains the risk of a depressive relapse. The occurrence of paranoid or schizophreniform psychosis is a recognised potential side effect, but no such disorder was precipitated in case 3, despite the fact that he had a history of paranoid illness. He had deteriorated to the point where he was very nearly akinetic, and mute, and so a trial of bromocriptine was considered justified, despite the risk of psychosiS.
In addition to the abulic syndrome, which was common to these patients, it is interesting to note the additional features which also responded to dopamine agonists. very severe amnestic state, or severe global cognitive impairment. Case 2 was severely amnestic but did not improve to the point where the moderate increase in his spontaneity became a problem, and case 4 had impairment but not complete loss of learning ability.
Finally, whilst the results of treatment in the cases reported here are encouraging, there is clearly a need and indication for placebo controlled trials in this area, probably of a single case design.
